Effects of carbamazepine coadministration on plasma concentrations of trazodone and its active metabolite, m-chlorophenylpiperazine

Ther Drug Monit. 1996 Apr;18(2):164-7. doi: 10.1097/00007691-199604000-00010.

Abstract

Effects of carbamazepine coadministration on plasma concentrations of trazodone and its active metabolite, m-chlorophenylpiperazine (m-CPP) were studied in six depressed patients treated with trazodone. The daily dose of trazodone was 150 mg in three cases and 300 mg in three cases. Carbamazepine, 400 mg/day, was coadministered for 4 weeks, and blood samples were taken before carbamazepine addition and at weekly intervals after the addition. Carbamazepine significantly (p < 0.01) decreased plasma concentrations of not only trazodone but also m-CPP at each week. On the average, plasma concentrations of trazodone and m-CPP at 4 weeks were 24 and 40% of the corresponding precarbamazepine values. This study thus suggests that carbamazepine coadministration decreases plasma concentrations of trazodone and m-CPP by inducing the metabolism of these compounds.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anticonvulsants / administration & dosage
  • Anticonvulsants / pharmacology*
  • Antidepressive Agents, Second-Generation / administration & dosage
  • Antidepressive Agents, Second-Generation / blood*
  • Carbamazepine / administration & dosage
  • Carbamazepine / pharmacology*
  • Female
  • Humans
  • Male
  • Middle Aged
  • Piperazines / analysis
  • Piperazines / metabolism
  • Serotonin Receptor Agonists / analysis
  • Serotonin Receptor Agonists / metabolism
  • Trazodone / administration & dosage
  • Trazodone / blood*

Substances

  • Anticonvulsants
  • Antidepressive Agents, Second-Generation
  • Piperazines
  • Serotonin Receptor Agonists
  • Carbamazepine
  • 1-(3-chlorophenyl)piperazine
  • Trazodone